Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
June 15, 2022 16:01 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China
June 15, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University
May 23, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome
April 25, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., April 25, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome
March 15, 2022 08:41 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome
March 10, 2022 08:00 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome
March 01, 2022 08:00 ET
|
Quoin Pharmaceuticals, Inc.
ER-Kim Gains Exclusive Rights to Commercialize QRX003 to Six Additional Countries 60 Countries Now Covered by Partnership Agreements for QRX003 ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) --...
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome
February 17, 2022 08:00 ET
|
Quoin Pharmaceuticals, Inc.
Neopharm Gains Exclusive Rights to Commercialize QRX003 in IsraelSixth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb. 17, 2022 (GLOBE NEWSWIRE)...
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome
February 10, 2022 08:00 ET
|
Quoin Pharmaceuticals, Inc.
- ER-Kim Gains Exclusive Rights to Commercialize QRX003 Across Central & Eastern Europe - Fifth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb....
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome
January 26, 2022 08:00 ET
|
Quoin Pharmaceuticals, Inc.
- OrphanDC Gains Exclusive Rights to Commercialize QRX003 in Key Countries in Latin America- Fourth Distribution Partnership Established Since Going Public in October 2021- Additional Territories in...